Physician profile
Taylor Tran
NPI 1366699274
$1,630.97
in general payments reported to CMS, 2019-2025
15 companies · $1,176 in 2025
The $1,176 reported for 2025 was more than what 98% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2021: $16.45 · 2022: $17.20 · 2023: $73.59 · 2024: $170 · 2025: $1,176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $888 · Food and Beverage: $532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $887.89 |
| Food and Beverage | $532.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Modernatx, INC. | $916.78 | 2025 | Spikevax |
| Glaxosmithkline, LLC. | $189.34 | 2019-2025 | Bexsero, Penmenvy, Pediarix |
| Merck Sharp & Dohme LLC | $133.40 | 2024-2025 | M-M-R II, Vaxelis, Rotateq |
| Alk-Abello, INC | $74.69 | 2025 | Neffy |
| Teva Pharmaceuticals USA, INC. | $64.01 | 2019 | |
| Amgen INC. | $50.13 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $42.16 | 2024 | Flumist Quadrivalent |
| Sanofi Pasteur INC. | $36.13 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $23.36 | 2023 | |
| Ars Pharmaceuticals Operations, INC. | $22.22 | 2025 | Neffy |
| Gilead Sciences, INC. | $16.90 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.36 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $16.20 | 2023 | Kristalose |
| Kowa Pharmaceuticals America, INC. | $15.61 | 2025 | Zoryve |
| Kaleo, INC. | $13.68 | 2024 | Auvi-Q |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.